Literature DB >> 16953219

Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation.

R A Jones1, C I Campbell, E J Gunther, L A Chodosh, J J Petrik, R Khokha, R A Moorehead.   

Abstract

Overexpression and hyperactivation of the type I insulin-like growth factor receptor (IGF-IR) has been observed in human breast tumor biopsies. In addition, in vitro studies indicate that overexpression of IGF-IR is sufficient to transform cells such as mouse embryo fibroblasts and this receptor promotes proliferation and survival in breast cancer cell lines. To fully understand the function of the IGF-IR in tumor initiation and progression, transgenic mice containing human IGF-IR under a doxycycline-inducible MMTV promoter system were generated. Administration of 2 mg/ml doxycycline in the animals' water supply beginning at 21 days of age resulted in elevated levels of IGF-IR in mammary epithelial cells as detected by Western blotting and immunohistochemistry. Whole mount analysis of 55-day-old mouse mammary glands revealed that IGF-IR overexpression significantly impaired ductal elongation. Moreover, histological analyses revealed multiple hyperplasic lesions in the mammary glands of these 55-day-old mice. The formation of palpable mammary tumors was evident at approximately 2 months of age and was associated with increased levels of IGF-IR signaling molecules including phosphorylated Akt, Erk1/Erk2 and STAT3. Therefore, these transgenic mice provide evidence that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumor formation in vivo and provide a model to further understand the function of IGF-IR in mammary epithelial transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953219     DOI: 10.1038/sj.onc.1209955

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

2.  Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; D De León
Journal:  Growth Horm IGF Res       Date:  2010-03-27       Impact factor: 2.372

3.  Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

Authors:  Rulla M Tamimi; Graham A Colditz; Yihong Wang; Laura C Collins; Rong Hu; Bernard Rosner; Hanna Y Irie; James L Connolly; Stuart J Schnitt
Journal:  Breast Cancer Res Treat       Date:  2011-01-01       Impact factor: 4.872

4.  Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation.

Authors:  Subhalakshmi Ganguly; Biswarup Basu; Saurav Shome; Tushar Jadhav; Sudipta Roy; Jahar Majumdar; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 4.307

Review 5.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

6.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

7.  IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.

Authors:  Lauren M Rota; Lidia Albanito; Marcus E Shin; Corey L Goyeneche; Sain Shushanov; Emily J Gallagher; Derek LeRoith; Deborah A Lazzarino; Teresa L Wood
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

Review 8.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

9.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

10.  Extracellular vesicles from MDA-MB-231 breast cancer cells stimulated with insulin-like growth factor 1 mediate an epithelial-mesenchymal transition process in MCF10A mammary epithelial cells.

Authors:  Elizabeth Leal-Orta; Javier Ramirez-Ricardo; Alejandra Garcia-Hernandez; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  J Cell Commun Signal       Date:  2021-07-26       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.